“One of the most challenging oncologic situations is the diagnosis of breast cancer in a young pregnant patient,” Jacqueline Jeruss, MD, PhD, Associate Dean, Regulatory Affairs; Director of the Breast Care Center; and Professor of Surgery, Pathology, and Biomedical Engineering at the University of Michigan, Ann Arbor, told the more than 250 oncologists, psychologists, genetic counselors, and others attending the 2016 Oncofertility Conference in Chicago.1
“There is a breast cancer diagnosis in about 1 in every 3,000 pregnancies.”— Jacqueline Jeruss, MD, PhD
Tweet this quote
“There is a breast cancer diagnosis in about 1 in every 3,000 pregnancies,” Dr. Jeruss reported, and the numbers may increase as childbearing is delayed. These patients cannot be managed like other new patients with breast cancer but rather “need additional time to process their treatment decisions,” she said.
Breast cancers detected during pregnancy tend to be more advanced, Dr. Jeruss noted, because these young women are not typically being screened for breast cancer. For these women, the most common mode of detection is a patient-identified palpable finding.
“Management options and recommendations are fluid,” Dr. Jeruss noted, because of advances in neonatal care and changes in our understanding of who needs treatment. Treatment decisions must balance the need for treatment (the health of the mother) along with the impact of treatment (the health of the fetus). Surgery, chemotherapy, radiation therapy, and endocrine therapy “all have a potential impact on the developing fetus,” Dr. Jeruss stated.
Make No Assumptions
Initial discussions about pregnancy and future fertility have to be introduced into the already very complicated issues associated with a new diagnosis of breast cancer. Physicians need to explain the recommended treatment guidelines and also to listen carefully to understand the patient’s goals concerning her own health, ongoing pregnancy, and future childbearing.
“It is important not to assume that fertility preservation is not desired” based on a patient’s age, marital or partner status, or because she already has one or more children, Dr. Jeruss explained. Failure to address concerns about fertility preservation “could be a stopping point” for a patient, who might then decide not to proceed with treatment. “It is critical that we talk about these issues and break through potential preconceptions and move beyond them,” she emphasized.
In an interview with The ASCO Post, Dr. Jeruss and Teresa K. Woodruff, PhD, talked about the importance of discussing all reproductive health issues with women diagnosed with breast cancer and who are pregnant or may become pregnant. Dr. Woodruff is Director of the Oncofertility Consortium, Northwestern University and one of the 2016 Oncofertility Conference Chairs.
“Having discussions about contraception—both hormonal and barrier methods—is important.”— Teresa K. Woodruff, PhD
Tweet this quote
These reproductive health issues include contraception. “Having discussions about contraception—both hormonal and barrier methods—is important,” Dr. Woodruff said. “So, even in hormonally responsive cases, there are options for contraception.”
“We need to be mindful that patients have many different life goals,” Dr. Jeruss commented. Patients need to know that physicians recognize and respect their autonomy.
Early Discussion Important
“Oncologists should engage their patients in discussions about fertility concerns as they relate to treatment at the earliest possible time point,” Dr. Jeruss stressed. “Breast cancer treatment contributes to or may cause infertility,” she noted, and “surgical procedures and radiation therapy can also have ramifications on future pregnancies in terms of breastfeeding and reconstruction options.”
Dr. Jeruss would like to see a day when referrals for oncofertility services are regarded as similar to referrals for reconstruction or genetic testing and counseling. “We need to have a multidisciplinary approach that includes surgical oncologists and medical oncologists, along with fertility specialists, to ensure that the continuum of care is as seamless as possible,” she noted.
Fertility Preservation Options
Embryo and oocyte cryopreservation are both now considered standard fertility preservation procedures. Embryo cryopreservation “is associated with the most robust and long-term outcomes data,” Dr. Jeruss noted. Ovarian tissue cryopreservation is still considered experimental and is being performed only in institutions with research study protocols, she added.
The ASCO Post launched 10 years ago at the 2010 ASCO Annual Meeting. In celebration of the milestone, we’ve been publishing a retrospective series of article selections, looking back at some of the highlights published over the past decade. This article was originally published in The ASCO Post on January 25, 2017.
We would love to hear what The ASCO Post means to you and how we may continue to serve the needs and interests of our readers. Contact editor@ASCOPost.com.
“Timing is critical,” Dr. Jeruss stressed. Oocyte harvesting can be performed before or after surgery. “We need to be time sensitive about fertility discussions particularly for patients who are to have neoadjuvant chemotherapy, before surgery,” she added. In these situations, she continued, “we need to have partnerships with fertility preservation specialists, so patients can come in at the earliest possible time, undergo fertility preservation, and then initiate chemotherapy.”
Breast cancer treatment, including surgery, chemotherapy, radiation therapy, and then tamoxifen, “could last up to 10 years from the time of diagnosis,” Dr. Jeruss pointed out. She also reported that several studies using retrospective data have showed a subsequent pregnancy is not associated with an increased risk of recurrence or poorer survival among patients with breast cancer.
Discussions During Pregnancy
When discussing treatment options with a woman who is pregnant at the time of breast cancer diagnosis, “I’ve had to take a step back and be sure that I am broad-minded about what she may wish for, along with my recommendations for her care,” Dr. Jeruss said. Factors to consider include the diagnosis, stage of disease when diagnosed, hormone receptor status, and trimester.
First Trimester: “Surgery with mastectomy is the primary option for women diagnosed with breast cancer while in their first trimester of pregnancy,” Dr. Jeruss said. “Chemotherapy initiation does not typically occur until the second trimester. In the first trimester, fetal monitoring during surgery is typically not implemented,” she added.
The use of lymphatic mapping with dye throughout pregnancy remains controversial. Dr. Jeruss said the use of a radioactive tracer has not been found to impact the fetus, but analyses have been limited by small sample sizes.
“Some patients want reconstruction, but we tend to tell them that the first trimester is not the optimal time when trying to limit anesthetic exposure for patients and fetuses as much as possible,” Dr. Jeruss noted. Breast-conserving surgery is not typically recommended because radiation therapy would be delayed for several months.
“So, there are limits to what we can offer these patients in the first trimester,” Dr. Jeruss remarked. “Surgery can be implemented with a very clear consent process. There is typically no role for chemotherapy, radiation therapy, or tamoxifen.” If adjuvant treatment is to follow, chemotherapy and radiation therapy will be delayed for several months, and tamoxifen would be delayed until pregnancy is completed.
“Although it is a difficult conversation to have, termination of pregnancy can also be mentioned for these patients. Such talks can have significant ramifications—both religious and psychological—and require great sensitivity.”
Second Trimester: Mastectomy remains the primary surgical option for women with breast cancer in the second trimester, Dr. Jeruss said. “Organogenesis has largely occurred,” she noted, “and now we can start to talk about the use of chemotherapy. However, radiation therapy and tamoxifen are still not recommended.”
When performing surgery for women in their second trimester, the surgical oncologist should “work in collaboration with a neonatal group that will implement fetal monitoring and have that team available, in case the patient has preterm labor,” Dr. Jeruss advised. Reconstruction is generally not recommended.
Chemotherapy, surgery, and then delivery is “an accepted treatment plan for patients diagnosed in the second trimester,” according to Dr. Jeruss. Other sequential options are surgery, chemotherapy, and then delivery, or surgery, delivery, chemotherapy. All sequences may involve some delay in treatment.
“If a patient is BRCA-positive, the timing of a contralateral mastectomy becomes another issue, and this procedure tends to be deferred until after delivery,” Dr. Jeruss said.
Third Trimester: For patients diagnosed in the third trimester, Dr. Jeruss said, “the plan is often to deliver the baby as soon as it is safe to do so. The recommended breast cancer treatment plan should not be significantly altered.”
The critical time period during the third trimester is between 27 and 35 weeks. “By 34 to 35 weeks, the lungs are often mature, and delivery can be considered,” Dr. Jeruss said.
Patients interested in breast conservation can be offered lumpectomy with the intent to initiate radiation therapy, particularly for patients who have reached the middle of the third trimester. “During surgery, a neonatal/high-risk obstetric team should be standing by with fetal monitoring throughout the operative case,” Dr. Jeruss advised.
Patients With BRCA-Positive Disease
Women with brca1 orBRCA2 mutations have a significantly elevated risk for developing breast cancer, Dr. Jeruss noted. Although the timing of breast cancer is unpredictable, the mean age at diagnosis for BRCA carriers is in their early 40s, compared with around age 60 for noncarriers.
“Primary treating oncologists have a responsibility to take the initiative in discussing fertility preservation options with these patients,” Dr. Jeruss stated. “Early referral for fertility preservation consultation gives patients the greatest potential autonomy regarding this critical issue.”
For BRCA carriers, risk-reduction surgery should be done “at the earliest possible time that the patient feels ready to proceed,” Dr. Jeruss commented. “These patients can feel a tremendous amount of internal and external pressure to make critical decisions that will be irreversible in terms of childbearing. So, it is important to be sensitive to those issues when they arise.”
Bilateral salpingo-oophorectomy is generally recommended after childbearing has been completed, but “some patients may opt for oocyte harvest, bilateral salpingo-oophorectomy, and subsequent pregnancy with in vitro fertilization, potentially using a surrogate, based on family history,” said Dr. Jeruss. Alternative plans, such as the use of a donor egg and adoption, should also be discussed.
Mastectomy can be planned before or after pregnancy, “depending on how the patient feels most comfortable moving forward,” Dr. Jeruss suggested. Advantages of mastectomy before pregnancy include decreased screening once the woman is pregnant and a decreased likelihood of diagnostic imaging and biopsy, along with a decreased risk for a new cancer diagnosis. A consequence of mastectomy before pregnancy, Dr. Jeruss said, is that “breastfeeding will not be possible, and this must be clearly explained prior to surgery.”
“Tamoxifen is an incredibly important treatment for patients over the long-term survivorship period,” Dr. Jeruss noted, but it is a teratogen, and “pregnancy should be avoided during the 5 to 10 years of recommended tamoxifen use.” The considerable length of recommended treatment may be a deterrent to breast cancer survivors hoping to become pregnant.
To look at factors that could influence the decision about tamoxifen use in younger patients, researchers at the University of Michigan and Northwestern Medicine reviewed charts of 987 patients aged 45 and younger when diagnosed with estrogen receptor–positive breast cancer. “We found that having a diagnosis of ductal carcinoma in situ, being noncompliant with other cancer therapies, as well as having a desire for future fertility correlated with those patients who were not going to initiate tamoxifen,” Dr. Jeruss reported.
The reasons cited by patients who did not follow recommendations to take tamoxifen were concerns about side effects and, nearly as frequently, fertility concerns, Dr. Jeruss reported. Concerns about fertility were also cited by patients who started the drug and then stopped it.
Patients who delay initiating tamoxifen and or discontinue tamoxifen therapy can still receive benefits of reduced risk of recurrence and mortality.2,3 “Some data support the potential for a tailored delay in tamoxifen therapy, allowing time for pregnancy, with expectation to ultimately complete 5 to 10 years of therapy, though this is an area of active study,” Dr. Jeruss said.
DISCLOSURE: Drs. Jeruss and Woodruff reported no conflicts of interest.
2. Love RR, Olsen MR, Havighurst TC: Delayed adjuvant tamoxifen in postmenopausal women with axillary node-negative breast cancer: Mortality over 10 years. J Natl Cancer Inst 91:1167-1168, 1999.
3. Gradishar WJ, Helmund R: A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy. Clin Breast Cancer 2:282-286, 2002.